ALSO NOTED: BioVeris to collaborate with UMass; Genentech seeks expanded Rituxan use; Antisoma wins orphan status; and much mor
> BioVeris is collaborating with researchers at the University of Massachusetts to find a vaccine for chlamydia. BioVeris will have exclusive patent rights and UMass gets $600,000 in research funds. Report
> Genentech and Biogen Idec are seeking expanded use of Rituxan. Release
> The UK's Antisoma announced that the FDA had given its experimental drug for renal cancer orphan drug status. Story
> Australia's Giaconda hopes to raise $6 million in an IPO. Story
> Genstruct has reached its first milestone with Pfizer. Release
> Lundbeck's operating profits have fallen. Story
And Finally… Oregon has implemented a new law that requires a prescription for most cold remedies that can be used to make methamphetamines. Article
More stories about FDA Genentech Experimental Drugs Pfizer Rituxan Biogen Idec orphan drug status Antisoma Biotech IPO


SHARE
WITH: